



IMPORTANT TEST NOTICE UPDATE:

Dear Valued Client;

As indicated in earlier communications, the Mycobacteriology Laboratory at National Jewish Health is aligning its interpretations of susceptibility tests to the Clinical and Laboratory Standards Institute (CLSI) for mycobacteria and aerobic actinomycetes. We are happy to announce that in addition to rapidly growing mycobacteria that went into effect on March 31, 2020, and the alignment of the *M. avium complex* that went into effect on July 1, 2020, the minimum inhibitory concentrations and CLSI interpretive breakpoints for *Nocardia* species and other aerobic actinomycetes has been completed and can be requested by selecting laboratory test code NTM4. Reporting of the new MICs and breakpoints started on January 20, 2021. The migration of the remaining slowly growing mycobacteria to CLSI interpretations will occur in phases over the next few months.

As a result of the alignment project, NTM4 (15-drug panel) is no longer available for ordering on rapidly growing mycobacteria. For sensitivity testing on rapidly growing mycobacteria, select test code NTM6 for the full 21-drug panel or NTM5 for a custom panel. These changes will be reflected on the new Mycobacteriology Laboratory requisition scheduled to release in February 2021.

If you have any questions, please contact our Client Service Team at 800-550-6227 or via email at ClinRefLabs@NJHealth.org.

Sincerely,

A handwritten signature in blue ink, appearing to read "Reeti Khare".

Reeti Khare, PhD, D(ABMM)
Director, Mycobacteriology and Respiratory Infections Laboratory
Advanced Diagnostics Laboratory, National Jewish Health

njlabs.org | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.